The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
Spectrum Solutions’ offerings enhanced by including CLIA/CAP laboratory testing, custom assay development, and manufacturing of industry-leading microarray chip technology. These valuable assets, ...
- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback